<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02015793</url>
  </required_header>
  <id_info>
    <org_study_id>M14-232</org_study_id>
    <nct_id>NCT02015793</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics in
      Chinese subjects with Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To characterize the pharmacokinetics of two dosing regimens of adalimumab</measure>
    <time_frame>At Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adalimumab serum concentrations will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory Test Variables</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hematology, Chemistry, and Urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Sign Variables</measure>
    <time_frame>From Week 0 to Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood Pressure, heart rate, respiratory rate, and body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to 70 days after Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of anti-adalimumab antibody (AAA)</measure>
    <time_frame>Up to Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>AAA concentrations will be measured.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Standard induction dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given the standard loading dose of adalimumab at Weeks 0 and 2 followed by the standard maintenance dose beginning at week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low induction dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given a low loading dose of adalimumab at Weeks 0 and 2 followed by the standard maintenance dose beginning at week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subjects will be given subcutaneous injections of adalimumab.</description>
    <arm_group_label>Standard induction dose</arm_group_label>
    <arm_group_label>Low induction dose</arm_group_label>
    <other_name>Humira®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of Chinese decent with full Chinese parentage.

          2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by
             endoscopy, radiologic evaluation, and/or histology during the Screening Period.

          3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral
             corticosteroids and/or immunosuppressants.

          4. Subject has a negative Tuberculosis (TB) Screening Assessment.

        Exclusion Criteria:

          1. Subject with ulcerative colitis or indeterminate colitis.

          2. Subject who has had a surgical bowel resection within the past 6 months or who is
             planning any resection at any time point in the future.

          3. Subject with an ostomy or ileoanal pouch.

          4. Subject who has short bowel syndrome.

          5. Subject with symptomatic known obstructive strictures.

          6. Subject with an internal or external fistula (with the exception of an anal fistula
             without abscess).

          7. Chronic recurring infections or active TB.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roopal  Thakkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie  Tokimoto</last_name>
    <email>debbie.tokimoto@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tonee  Puetz</last_name>
    <email>tonee.puetz@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119755</name>
      <address>
        <city>Beijing</city>
        <zip>1000700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119755</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118498</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118498</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118496</name>
      <address>
        <city>Guangdong</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118496</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118497</name>
      <address>
        <city>Guangzhou, Guangdong</city>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118497</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118500</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118500</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118502</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118502</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118275</name>
      <address>
        <city>Shanxi Province</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118275</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
